Piramal Pharma Ltd.

“Piramal Pharma sits in the unattractive intersection of mediocre current economics and an expensive valuation: a leveraged CDMO cyclical with sub-WACC ROIC, near-zero free cash flow, and a management track record of missing margin guidance, trading at 76.9x forward P/E with no margin of safety. The structural CDMO and ADC opportunities are real, but they are owned by better-capitalised, higher-margin peers who will compound faster. The bear case — CDMO volumes stall, leverage bites, Carlyle exits create ongoing supply pressure — is not a tail risk but a plausible base case that the current price entirely ignores. For long-term investors, capital is far better deployed in higher-quality CDMO businesses or elsewhere entirely.”